Search
All Clinical Trials in Canada
A listing of 3895 clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
85 - 96 of 3895
A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease
Recruiting
The purpose of this study to evaluate the clinical efficacy of guselkumab in fistulizing, perianal Crohn's disease and to assess the overall safety of guselkumab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +152 locations
Conditions: Fistulizing Crohns Disease, Perianal Crohns Disease
Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta
Recruiting
The primary objective of this study is to evaluate the effect of romosozumab treatment for 12-months compared with bisphosphonate(s) on the number of clinical fractures at 12-months; the number of any fractures at 12-months and change in lumbar spine bone mineral density (BMD) Z-score at 6-months.
Gender:
ALL
Ages:
Between 5 years and 17 years
Trial Updated:
07/17/2025
Locations: Childrens Hospital of Alabama, Birmingham, Alabama +44 locations
Conditions: Osteogenesis Imperfecta
Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
Recruiting
The purpose of the study in Part 1 (dose escalation) and in Part 2 (dose expansion) is to determine the recommended Phase 2 dose(s) (RP2D\[s\]) and evaluate preliminary clinical efficacy. Part 3 (dose expansion) will confirm safety and preliminary clinical activity at the RP2D. Part 4 (RP2D expansion) will assess the overall complete response (CR) in participants with intermediate-risk-non-muscle invasive bladder cancer (IR-NMIBC; means the cancer cells are only in the bladder's inner lining).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: University of Southern California, Los Angeles, California +46 locations
Conditions: Urinary Bladder Neoplasms, Receptors, Fibroblast Growth Factor
A Study of HARMONIC 700 Shears With Advanced Hemostasis in Pediatric and Adult Surgical Procedures
Recruiting
The main purpose of this study is to demonstrate acceptable performance and assess safety of the HARMONIC 700 Shears device in a post-market setting when used per the instructions for use in pediatric and adult surgical procedures.
Gender:
ALL
Ages:
110 years and below
Trial Updated:
07/17/2025
Locations: Riley Hospital for Children at Indiana University Health, Indianapolis, Indiana +7 locations
Conditions: Pediatric Surgical Procedures, Adult Surgical Procedures, Adult Gynecological Procedures, Adult Urological Procedures, Adult Thoracic Procedures
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Recruiting
The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on invasive breast cancer-free survival (iBCFS), in a close to clinical practice patient population with HR-positive (HR+), HER2-negative (HER2-), Anatomic Stage Group III, IIB, and a subset of Stage IIA Early Breast Cancer (EBC).
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
07/17/2025
Locations: Alaska Oncology and Hematology LLC, Anchorage, Alaska +50 locations
Conditions: Early Breast Cancer
A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI)
Recruiting
The purpose of this study is to assess the socio-demographic, disease-related and treatment-related characteristics, and the standard of care (SOC) treatment patterns of participants with major depressive disorder (MDD) with anhedonia with inadequate response to their current antidepressant treatments and treated according to the standard of care treatment.
Gender:
ALL
Ages:
Between 18 years and 74 years
Trial Updated:
07/17/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +92 locations
Conditions: Depressive Disorder, Major
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
Recruiting
This study is designed to evaluate the long-term efficacy and safety of mirikizumab in participants with moderately to severely active ulcerative colitis (UC). The study will last up to 3 years. Participants who complete the 3-year study may continue to receive mirikizumab until it is (outside of this study) in their country or until they meet other discontinuation criteria.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/17/2025
Locations: Digestive Health Specialists, Dothan, Alabama +361 locations
Conditions: Ulcerative Colitis
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Recruiting
Researchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it works.
In this trial, the researchers want to learn how well BAY2927088 (sevabertinib) works in people with different types of solid tumors with HER2 mutations. These include tumors in the colon or rectum, the uterus and the cervix (lower part of the uterus),... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +53 locations
Conditions: Advanced Solid Tumors, HER2 Mutation
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis
Recruiting
The main purpose of this study is to investigate efficacy, pharmacokinetics and safety of the drug in pediatric participants with moderately to severely active ulcerative colitis (UC).
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
07/17/2025
Locations: Rady Children's Hospital- San Diego, San Diego, California +55 locations
Conditions: Ulcerative Colitis
Feasibility and Acceptability of an Evidence-Informed Virtual Intervention to Reduce Perceptions of Injustice Following Work Injury
Recruiting
Many individuals who have sustained disabling injuries in the workplace react to their situation with a sense of 'injustice'. Research over the past 20 years has revealed that, interpreting one's post-injury life situation as 'unjust', actually interferes with recovery from the disabling injury. Post-injury perceptions of injustice contribute to more severe pain, more severe symptoms of depression and PTSD, and more prolonged absence from work. Several clinical researchers have highlighted the n... Read More
Gender:
ALL
Ages:
Between 25 years and 65 years
Trial Updated:
07/17/2025
Locations: McGill University, Montreal, Quebec
Conditions: MSK Conditions
A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis
Recruiting
The purpose of this study is to characterize cardiac safety of Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone (D-VCd) treatment regimens (Arm A: daratumumab + immediate VCd treatment and Arm B: daratumumab + deferred VCd) in newly diagnosed systemic amyloid light chain (AL) amyloidosis with cardiac involvement and to identify potential mitigation strategies for cardiac toxicity (cohort 1); to characterize the pharmacokinetics of subcutaneous (SC) daratumumab, among racial and ethni... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: City of Hope, Duarte, California +45 locations
Conditions: Amyloidosis
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Recruiting
The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexamethasone (DRd).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: City of Hope Cancer Center, Duarte, California +206 locations
Conditions: Multiple Myeloma
85 - 96 of 3895